Evaluation of therapeutic effectiveness of 131I-antiEGFR-BSA-PCL in a mouse model of colorectal cancer

Figure 1 Confocal microscopy of LS180 cancer cells incubated with FITC-BSA-PCL and FITC-antiEGFR-BSA-PCL for 4 h.

Figure 2 ¹³¹I uptake in LS180 cells.

Figure 3 Changes in the animal body weight.

Figure 4 Changes in tumor volume.

Figure 5 Tissue distribution of ¹³¹I-antiEGFR-BSA-PCL, ¹³¹I-BSA-PCL and ¹³¹I.

Figure 6 Immunohistochemical staining of LS180 colorectal cancer.

Figure 7 Histopathology of the liver, spleen, and tumor tissue at 3 d after the end of the treatment (× 100).